A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations
The purpose of this study is to study the effects, good and bad, of the study drug INCB054828 on participants and their urothelial carcinoma.
Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations
≥18 years old with metastatic or surgically unresectable urothelial carcinoma. Further labs, scans, and review of medical history will be done to confirm eligibility.
18 - 120
Healthy Volunteers Needed
Duration of Participation
For as long as the participant is seeing benefit from the study drug
Knight Cancer Institute Clinical Trials